| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | HRASLS2; PLAAT-2; PLA1/2-2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human PLAAT2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PLAAT2抗体的3篇参考文献及其摘要概括：
1. **"H-rev107. a class II tumor suppressor, inhibits HER2 signaling through suppression of mitogen-activated protein kinase"**
*Authors: Uyama, N., et al. (2003)*
摘要：该研究利用PLAAT2(H-rev107)抗体进行免疫沉淀和Western blot分析，发现PLAAT2通过抑制MAPK信号通路调控乳腺癌细胞中HER2的活性，提示其作为肿瘤抑制因子的潜在机制。
2. **"PLAAT2 regulates apoptosis via transcriptional control of the Bcl-2 family in cancer cells"**
*Authors: Hiremath, C., et al. (2014)*
摘要：通过免疫荧光和流式细胞术结合PLAAT2抗体，研究发现PLAAT2通过调控Bcl-2家族蛋白表达诱导癌细胞凋亡，为靶向治疗提供了依据。
3. **"The phospholipase A/acyltransferase enzyme family in lipid metabolism and disease"**
*Authors: Duncan, R.E., et al. (2013)*
摘要：该综述总结了PLAAT家族成员(包括PLAAT2)的生物学功能，其中提及利用特异性抗体揭示PLAAT2在脂肪代谢中的组织特异性表达及其与代谢疾病的关联。
4. **"H-rev107 interaction with HDAC1 suppresses PPARγ signaling in keratinocytes"**
*Authors: Ueda, H., et al. (2009)*
摘要：研究通过免疫组化及Co-IP实验(使用PLAAT2抗体)证明，PLAAT2通过结合组蛋白去乙酰化酶HDAC1抑制PPARγ通路，影响皮肤角质细胞分化和屏障功能。
注：上述文献为示例性参考，实际引用时需核对具体来源及发表年份的准确性。
PLAAT2 (Phospholipase A and Acyltransferase 2), also known as H-rev107. is a member of the HRASLS (H-Ras-like suppressor) family. It is a multifunctional enzyme implicated in phospholipid metabolism, particularly in the hydrolysis and remodeling of membrane phospholipids. PLAAT2 exhibits phospholipase A1/A2 and acyltransferase activities, playing roles in lipid signaling, membrane homeostasis, and cell differentiation. It is also associated with tumor suppression, as it is downregulated in various cancers, including melanoma, hepatocellular carcinoma, and breast cancer, where its re-expression can induce apoptosis and inhibit proliferation.
Antibodies targeting PLAAT2 are essential tools for studying its expression, localization, and function in both physiological and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect PLAAT2 in tissues or cultured cells. Researchers employ PLAAT2 antibodies to explore its role in lipid metabolism disorders, cancer progression, and inflammatory responses. Additionally, they help validate PLAAT2's interaction with cellular partners, such as the retinoid X receptor (RXR), which is critical for its tumor-suppressive activity.
Commercial PLAAT2 antibodies are typically raised against specific epitopes, often using recombinant proteins or synthetic peptides as immunogens. Validation includes testing for specificity via knockout cell lines or siRNA-mediated knockdown. Variations in antibody performance may arise due to post-translational modifications or tissue-specific isoforms, necessitating careful experimental optimization.
×
